The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

Claims 1-22. (Cancelled).

23. (Previously presented) A method of administering a pharmaceutically effective dose of aerosolized tetrahydrocannabinol to a patient, comprising the steps of:

providing a solution comprising a pharmaceutically acceptable form of said tetrahydrocannabinol in a hydrofluoroalkane, said solution having not more than 15% of a pharmaceutically acceptable solvent;

aerosolizing said solution to provide respirable droplets comprising said tetrahydrocannabinol, wherein at least 20% of the mass of said respirable droplets comprise droplets having an aerodynamic diameter of less than 5.8 μm;

administering a pharmaceutically effective dose of said respirable droplets to said patient's lungs.

24. (Previously presented) The method of claim 23 wherein said tetrahydrocannabinol is present in pharmaceutically pure form.

25. (Previously presented) The method of claim 23 wherein said tetrahydrocannabinol is a pharmaceutically acceptable salt of said tetrahydrocannabinol.

26. (Previously presented) The method of claim 23 wherein said pharmaceutically acceptable solvent comprises ethanol.

27. (Previously presented) The method of claim 23 wherein said solution consists essentially of said hydrofluoroalkane and said tetrahydrocannabinol.

28. (Previously presented) The method of claim 23 wherein said solution is surfactant free.

29. (Previously presented) The method of claim 23 wherein said tetrahydrocannabinol is present in said solution at a concentration sufficient to achieve serum concentration levels in said patient of 10-100 ng/ml fifteen minutes following inhalation.

30. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to treat nausea.

31. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to treat vomiting.

32. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to reduce pain.

33. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to relieve muscle spasticity.

34. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to relieve migraine headaches.

35. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to relieve movement disorders.

36. (Previously presented) The method of claim 23 wherein said pharmaceutically effective dose is sufficient to increase appetite in patients suffering from cachexia.

37. (Previously presented) A method of administering a pharmaceutically effective dose of medical marijuana to a patient, comprising the steps of:

providing a solution comprising a pharmaceutically acceptable form of said medical

marijuana in a hydrofluoroalkane, said solution having not more than 15% of a pharmaceutically acceptable solvent;

aerosolizing said solution to provide respirable droplets comprising said medical marijuana, wherein at least 20% of the mass of the respirable droplets comprise droplets having an aerodynamic diameter of less than 5.8 μm;

administering a pharmaceutically effective dose of said respirable droplets to said patient's lungs.

38. (Previously presented) The method of claim 37 wherein said pharmaceutically acceptable solvent comprises ethanol.

39. (Previously presented) The method of claim 37 wherein said solution consists essentially of said hydrofluoroalkane and said medical marijuana.

40. (Previously presented) The method of claim 37 wherein said solution is surfactant free.

41. (Previously presented) The method of claim 37 wherein said medical marijuana is present in said solution at a concentration sufficient to achieve serum concentration levels in said patient of 10-100 ng/ml fifteen minutes following inhalation.

42. (Previously presented) The method of claim 37 wherein said pharmaceutically effective dose is sufficient to treat a condition selected from the group consisting of nausea, vomiting, pain, muscle spasticity, migraine headaches, movement disorders, and loss of appetite due to cachexia.

43.(Previously presented) A pharmaceutical composition comprising a hydrofluoroalkane, Δ^9-tetrahydrocannabinol, and up to 15 percent by weight of an organic solvent, said Δ^9-tetrahydrocannabinol and said organic solvent being dissolved in said hydrofluoroalkane to form a stable composition, wherein said Δ^9-tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w (±0.008) to 5.940% w/w (±0.191).

44. (Previously presented) The pharmaceutical composition of claim 43 wherein said Δ^9-tetrahydrocannabinol is present in pharmaceutically pure form.

45. (Previously presented) The method of claim 43 wherein said Δ^9-tetrahydrocannabinol is a pharmaceutically acceptable salt of said Δ^9-tetrahydrocannabinol .

46. (Previously presented) The pharmaceutical composition of claim 43 wherein said organic solvent comprises ethanol.

47. (Previously presented) The pharmaceutical composition of claim 43 wherein said solution consists essentially of said hydrofluoroalkane and said Δ^9-tetrahydrocannabinol.

48. (Previously presented) The pharmaceutical composition of claim 43 wherein said stable composition is surfactant free.

49. (Previously presented) The pharmaceutical composition of claim 43 wherein said Δ^9-tetrahydrocannabniol is present in said stable composition at a concentration sufficient to achieve serum concentration levels in a patient of 10-100 ng/ml fifteen minutes following inhalation.

50. (Previously presented) A pharmaceutical composition comprising a hydrofluoroalkane, a tetrahydrocannabinol , and up to 15 percent by weight of an organic solvent, said tetrahydrocannabinol and said organic solvent being dissolved in said hydrofluoroalkane to form a stable composition, wherein said tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w (±0.008) to 5.940% w/w (±0.191).

51. (Previously presented) The pharmaceutical composition of claim 50 wherein said tetrahydrocannabinol is present in pharmaceutically pure form.

52. (Previously presented) The method of claim 50 wherein said tetrahydrocannabinol is a pharmaceutically acceptable salt of said tetrahydrocannabinol.

53. (Previously presented) The pharmaceutical composition of claim 50 wherein said organic solvent comprises ethanol.

54. (Previously presented) The pharmaceutical composition of claim 50 wherein said solution consists essentially of said hydrofluoroalkane and said tetrahydrocannabinol.

55. (Previously presented) The pharmaceutical composition of claim 50 wherein said stable composition is surfactant free.

56. (Previously presented) The pharmaceutical composition of claim 50 wherein said tetrahydrocannabinol is present in said stable composition at a concentration sufficient to achieve serum concentration levels in a patient of 10-100 ng/ml fifteen minutes following inhalation.